Post on 26-Jul-2020
EU Health Priorities
Jurate SvarcaiteSecretary General PGEU
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
AustriaBelgiumBulgariaCroatiaCyprusCzech RepDenmarkEstoniaFinlandFranceGermanyGreeceHungaryIrelandItalyLuxembourgMalta
NetherlandsPolandPortugalRomaniaSlovakiaSloveniaSpainSwedenUnited Kingdom
Bosnia HerzegovinaFYR MacedoniaNorwaySerbiaSwitzerlandTurkeyUkraine
Pharmaceutical Group of European UnionMembers: Professional Bodies & Pharmacists’ Associations
2016: 33 Countries
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
1959 2016
400.000Community Pharmacists
160.000 Pharmacies
46 million
citizens visit a pharmacy every day
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
Mission of PGEU
PGEU, as a a rigorous, proactive & constructive stakeholder:
Ensures our shared vision of Community Pharmacy is reflected in EU policy and legislative developments
Advocates for the contribution community pharmacists make to health systems and to public health through the provision of health services and the promotion of the rational and appropriate use of medicines
Promotes and develops cooperation in Community Pharmacy among the European nations
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
How do we do this?
Working collaboratively with members to establish positions that reflect the view of the profession as a whole in Europe
Establishing & maintaining working relationships with other European & International stakeholders
Dedicated Secretariat who are central to the organisation
Keeping patient care as the central focus
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
EU Health Law
EU: complementary competence in health
Focus on Public Health (Art 168 TFEU): limited powers ‘towards improving health and preventing disease”
Legal competencies: standard blood (organ) products, organs, tissues and medicines
Respecting the MS responsibilities for organisation, delivery and financing of medical care
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
EU Single Market
Free movement:
People
Services
Goods
Capital
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
PGEU is involved in a number of legal dossiers…
Professional Recognition
Directive
Falsified Medicines Directive
Medical Devices Regulation Health Claims on
Botanicals
Veterinary medicines
Trade Agreements VAT Waste Directive
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
Professional Qualifications Recognition Directive (I)
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
Professional Qualifications Recognition Directive (II)
The scope of pharmacist activities:
(a) preparation of the pharmaceutical form of medicinal products;
(b) manufacture and testing of medicinal products;
(c) testing of medicinal products in a laboratory for the testing of medicinal products;
(d) storage, preservation and distribution of medicinal products at the wholesale stage;
(e) supply, preparation, testing, storage, distribution and dispensing of safe and efficacious medicinal products of the required quality in pharmacies open to the public;
(f) preparation, testing, storage and dispensing of safe and efficacious medicinal products of the required quality in hospitals;
(g) provision of information and advice on medicinal products as such, including on their appropriate use;
(h) reporting of adverse reactions of pharmaceutical products to the competent authorities;
(i) personalised support for patients who administer their medication;
(j) contribution to local or national public health campaigns;
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
Digital single market
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
PGEU
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
AMR a major European challenge Why is AMR a serious threat to society and economy?
25 000 patients die annually in the EU alone as a result of infections caused by resistant bacteria.
€1.5 billion euros each year extra healthcare costs and productivity losses due to multidrug-resistant bacteria in the EU.
The consumption of specific antibiotics used for treatment of multidrug-resistant bacterial infections has increased significantly between 2010-2014.
Some good news - There has been a significant decrease in antibiotic consumption in the community in 5 countries (Denmark, Luxembourg, Slovenia, Spain and Sweden).
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union EuropéenneSource: http://ec.europa.eu/dgs/health_food-safety/amr/docs/eb445_amr_generalfactsheet_en.pdf
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
Eurobarometer 2016
Source: http://ec.europa.eu/dgs/health_food-safety/amr/docs/eb445_amr_generalfactsheet_en.pdf
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
EAAD
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
National campaigns
PGEU GPUE Pharmaceutical Group of European Union
Groupement Pharmaceutique de l’Union Européenne
THANK YOUwww.pgeu.eu